Home
About
Overview
Sharing Data
ORCID
Help
History (4)
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
Immunochemistry
Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.
Phosphatidylserines
See All 4 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res. 2009 Aug 15; 15(16):5032-5039.
View in:
PubMed
subject areas
Animals
Auditory Brain Stem Implants
Clinical Trials as Topic
Cochlear Implants
Consensus
Drug Evaluation, Preclinical
Health Planning Guidelines
Humans
Meningeal Neoplasms
Meningioma
Neurofibromatosis 2
Time Factors
authors with profiles
James Howard Tonsgard